Armistice Capital Asset Manager Profile - aVenture Research
Armistice Capital is a global hedge fund specializing in long/short, value-oriented, and event-driven strategies. The firm primarily focuses on the healthcare and consumer sectors, leveraging its expertise to identify investment opportunities. Armistice Capital's approach combines thorough research with a keen understanding of market dynamics to generate returns for its investors.
The fund has made notable investments in several biotechnology and pharmaceutical companies, including 2seventy bio, Abeona Therapeutics, and Karyopharm Therapeutics. Armistice Capital typically engages in post-IPO equity rounds, demonstrating its commitment to supporting companies in their growth stages. The firm's portfolio reflects a strong emphasis on innovative therapies and cutting-edge medical technologies.
Portfolio Snapshot
Observed round participation, including acquisitions and grants. Current holdings, investor exits, and write-offs are not established.